Trivitron Healthcare eyes Rs 750 crore revenue in FY19

New Delhi: Domestic medical devices maker Trivitron Healthcare is looking to clock revenue of around Rs 750 crore in the current fiscal year, as it mulls inorganic growth in key focus areas, a top company official has said. Established in 1997, the Chennai-based company posted revenue of around Rs 650 crore in the last fiscal year.

“We are looking at a revenue of around Rs 750 crore for the current fiscal year,” Trivitron Healthcare Chairman and MD GSK Velu told .

The focus areas for the company are laboratory, imaging, intensive care, operating rooms and renal dialysis, he added.

Out of these, 80 per cent of the profits come from the areas of laboratory and imaging while others are emerging areas for the company, Velu said.

“Going forward laboratory and imaging will continue to be the focus areas for the company where we are looking for both organic and inorganic growth to push revenues,” he added.

When asked about the key products manufactured by the company, Velu said the number one product for the group is for new born screening.

Other products are X-ray machines, ultra sound machines in a joint venture with Hitachi, mamography machines, all diagnostic products and products for intensive care units and operation theatres, he added.

On being asked about the state of medical device sector in India, the intent is there but the gap between intent and action needs to be narrowed, Velu said, adding that the domestic medical device industry needs to be nurtured.

Trivitron Healthcare currently has with 9 USFDA, CE manufacturing facilities across five locations — Chennai, Mumbai, Pune, Ankara and Helsinki — and has over 1,500 employees.

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra